Core Viewpoint - The company currently has one synthetic biology and biocatalysis technology center, which includes a synthetic biology technology innovation laboratory focused on developing functional proteins for feed and sweeteners for food [1] Group 1 - The synthetic biology technology innovation laboratory is primarily used for research and development of functional proteins for animal feed and sweeteners for food [1] - The laboratory has a limited number of R&D projects, small investment amounts, and insufficient professional personnel, indicating it is still in the early stages of strain laboratory research [1] - There is a significant gap to scale-up production, and the laboratory does not currently meet industrialization conditions [1]

（原标题：蔚蓝生物(603739.SH)：合成生物学产品的生产涉及分离、提纯等生产工艺，公司目前尚不 具备该工艺） 格隆汇11月24日丨蔚蓝生物(603739.SH)在投资者互动平台表示，合成生物学产品的生产涉及分离、提 纯等生产工艺，且提纯工艺难度较大，公司目前尚不具备该工艺，有待进一步开发。同时，产品未来还 可能涉及注册及法规审批、选品及市场推广等，周期较长，难度较大，商业化存在重大的不确定性。预 计在较长的时间，不会对公司的经营产生重大的影响。 ...

Core Insights - The phytic acid enzyme market is experiencing significant growth, primarily driven by increased demand in the feed industry, especially after the ban on antibiotics in animal feed in China in 2020, positioning phytic acid enzymes as ideal alternatives [1][7] - China's annual production of phytic acid enzymes has significantly increased, from 43,200 tons in 2015 to an expected 120,600 tons by 2024, indicating a robust growth trajectory [1][8] - The global phytic acid enzyme market is projected to grow from $513 million in 2023 to $822 million by 2029, with a compound annual growth rate (CAGR) of 8.2% [6] Industry Overview - Phytic acid enzymes belong to the class of phosphoric monoester hydrolases and are crucial for enhancing the bioavailability of minerals in plant-based feeds by breaking down phytic acid [2] - The industry has evolved through three stages: initial development in the 1990s, rapid growth from 2001 to 2012, and a mature phase from 2013 onwards, with domestic products replacing imports and achieving international technical standards [3][4] Industry Chain - The upstream of the phytic acid enzyme industry includes raw materials such as wheat, barley, and microorganisms, while the downstream applications span food, pharmaceutical, and feed industries [5] - The feed industry is the largest application area for phytic acid enzymes, driven by the need to improve feed efficiency and reduce costs, with a notable increase in China's feed production reaching 250.7 million tons in the first nine months of 2025, up 6.4% year-on-year [5][6] Competitive Landscape - The global phytic acid enzyme market is highly competitive, with companies like Novozymes, DuPont, and DSM holding significant market shares due to their technological advantages and patent protections [8] - Chinese companies such as Blue Horizon Biotechnology, Yidali, and Xinghuo Technology are emerging as strong competitors, gradually capturing high-end market segments [8] Development Trends - Technological innovation is a key driver for the industry, with advancements in enzyme production and purification methods expected to enhance yield and efficiency [10] - The application of phytic acid enzymes is expanding beyond traditional uses in poultry and pig feed to include aquaculture and organic agriculture, indicating new growth opportunities [11] - Environmental sustainability is becoming increasingly important, with stricter regulations prompting phytic acid enzyme companies to enhance their eco-friendly practices and production processes [12]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-054 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 （1）保证期间根据主合同项下债权人对债务人所提供的每笔融资分别计算，就每笔融资而言，保证期 间为该笔融资项下债务履行期限届满之日起三年。 重要内容提示： ● 担保对象及基本情况 （一）担保的基本情况 2025年11月20日，青岛蔚蓝生物股份有限公司（以下简称"公司"）与兴业银行股份有限公司青岛分行签 署了《最高额保证合同》，为公司全资子公司青岛蔚蓝生物集团有限公司（以下简称"蔚蓝生物集团"） 在该行开展的授信业务提供连带责任保证担保，担保总额为人民币8,000.00万元。 （二）内部决策程序 上述担保事项已经公司2025年4月25日召开的第五届董事会第十六次会议审议通过，并经公司于2025年5 月16日召开的2024年年度股东会批准。具体内容详见公司分别于2025年4月26日、2025年5月17日在上海 证券交易所网站披露的《青岛蔚蓝生物股份有限公司关 ...

证券日报网讯 11月21日晚间，蔚蓝生物发布公告称，2025年11月20日，公司与兴业银行股份有限公司 青岛分行签署了《最高额保证合同》，为公司全资子公司青岛蔚蓝生物集团有限公司在该行开展的授信 业务提供连带责任保证担保，担保总额为人民币8，000.00万元。 （文章来源：证券日报） ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-054 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | 青岛蔚蓝生物集团有限公司 | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 8,000.00 | 万元 | | | 担保对象 | 实际为其提供的担保余额 | 26,355.49 | 万元 | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | 本次担保是否有反担保 | 是 | □否 | □不适用：_________ | 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股 | 123,020.00 | | 子公司对外担保总额（万元） | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 70.79 ...

Core Viewpoint - The company has signed a guarantee contract with Industrial Bank Qingdao Branch to provide a joint liability guarantee for its wholly-owned subsidiary's credit business of 80 million yuan, which has been approved by the board and shareholders [1] Financial Summary - As of the announcement date, the company's actual guarantee balance is 263.55 million yuan, and the total external guarantees provided by the company and its subsidiaries amount to 1.23 billion yuan, representing 70.79% of the audited net assets as of the end of 2024, with no overdue guarantees [1] - For the period from January to September 2025, the revenue of the company is 728.50 million yuan, and the net profit is 117.32 million yuan [1]

Core Points - The company held its first extraordinary general meeting of shareholders on November 13, 2025, where no resolutions were rejected [2] - The meeting was chaired by the financial director due to the absence of the chairman and general manager [3] - The company approved the proposal to abolish the supervisory board and amend the articles of association, transferring the supervisory powers to the audit committee of the board [9] Meeting Details - The meeting took place at the company's innovation park in Qingdao [2] - The voting method combined on-site and online voting, complying with the Company Law and the company's articles of association [2] - Out of 5 current directors, 3 attended the meeting, while 1 supervisor attended out of 3 [3] Resolutions Passed - The following proposals were approved: - Abolishment of the supervisory board and amendment of the articles of association [4] - Amendments to various governance documents, including the rules for shareholder meetings, board meetings, independent director systems, and management of fundraising [4][5][6] - The proposals requiring special resolutions received over two-thirds of the votes from participating shareholders [6] Legal Confirmation - The meeting was witnessed by Beijing Hairun Tianrui Law Firm, confirming that the meeting's procedures complied with legal requirements [6]

Core Viewpoint - The company announced the election of Mr. Li Yuqiang as the employee representative director for the fifth board of directors during the employee representative meeting scheduled for November 13, 2025 [2] Group 1 - The employee representative meeting is set to take place on November 13, 2025 [2] - Mr. Li Yuqiang has been nominated for the position of employee representative director [2]

青岛蔚蓝生物股份有限公司 青岛蔚蓝生物股份有限公司董事会 关于选举第五届董事会职工代表董事的公告 2025 年 11 月 14 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 简历： 青岛蔚蓝生物股份有限公司（以下简称"公司"）于 2025 年 11 月 13 日召开 2025 年第一次临时股东会，审议通过了《关于取消监事会并修订<公司章程>的 议案》。本次修订后，公司不再设置监事会，其职权由董事会审计委员会行使， 同时在董事会中设立职工代表董事席位。 公司于同日召开职工代表大会，经与会职工代表审议，同意选举李玉强先生 为公司第五届董事会职工代表董事（简历见附件）。李玉强先生将与公司第五届 董事会非职工代表董事共同组成第五届董事会，任期自公司本次职工代表大会审 议通过之日起至第五届董事会届满之日止。 李玉强先生符合《公司法》等法律法规关于董事的任职资格和条件，并将按 照相关法律法规的规定行使职权。本次选举完成后，公司董事会中兼任公司高级 管理人员以及由职工代表担任的董事人数总计不超过公司董事总数的二分之一。 证券代码：60 ...